AveX­is shares spike on more pos­i­tive da­ta for SMA gene ther­a­py; Bio­gen stock tanks on fresh skep­ti­cism

→ AveX­is $AVXS says that 12 of the 12 in­fants suf­fer­ing from spinal mus­cu­lar at­ro­phy (SMA) who were treat­ed with AVXS-101 reached 13.6 months of age event free. And 9 of 9 reached 20 months event free. The com­pa­ny says that on­ly about one in four in­fants reach­es 13.6 months with­out an event. The biotech is push­ing ahead with a small piv­otal tri­al of a gene ther­a­py that is at­tract­ing a grow­ing amount of at­ten­tion. Their stock spiked 15% on the da­ta.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER